Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Correction to: Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens.

Schirmer U, Fiegl H, Pfeifer M, Zeimet AG, Müller-Holzner E, Bode PK, Tischler V, Altevogt P.

BMC Cancer. 2018 Oct 29;18(1):1047. doi: 10.1186/s12885-018-4928-y.

2.

The BH3-only protein BIM contributes to late-stage involution in the mouse mammary gland.

Schuler F, Baumgartner F, Klepsch V, Chamson M, Müller-Holzner E, Watson CJ, Oh S, Hennighausen L, Tymoszuk P, Doppler W, Villunger A.

Cell Death Differ. 2016 Jan;23(1):41-51. doi: 10.1038/cdd.2015.61. Epub 2015 Jun 5.

3.

L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.

Doberstein K, Milde-Langosch K, Bretz NP, Schirmer U, Harari A, Witzel I, Ben-Arie A, Hubalek M, Müller-Holzner E, Reinold S, Zeimet AG, Altevogt P, Fogel M.

BMC Cancer. 2014 Dec 15;14:958. doi: 10.1186/1471-2407-14-958.

4.

miR-21-3p is a positive regulator of L1CAM in several human carcinomas.

Doberstein K, Bretz NP, Schirmer U, Fiegl H, Blaheta R, Breunig C, Müller-Holzner E, Reimer D, Zeimet AG, Altevogt P.

Cancer Lett. 2014 Nov 28;354(2):455-66. doi: 10.1016/j.canlet.2014.08.020. Epub 2014 Aug 19.

PMID:
25149066
5.

In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors.

Tymoszuk P, Evens H, Marzola V, Wachowicz K, Wasmer MH, Datta S, Müller-Holzner E, Fiegl H, Böck G, van Rooijen N, Theurl I, Doppler W.

Eur J Immunol. 2014 Aug;44(8):2247-62. doi: 10.1002/eji.201344304. Epub 2014 Jun 16.

6.

High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer.

Tymoszuk P, Charoentong P, Hackl H, Spilka R, Müller-Holzner E, Trajanoski Z, Obrist P, Revillion F, Peyrat JP, Fiegl H, Doppler W.

BMC Cancer. 2014 Apr 12;14:257. doi: 10.1186/1471-2407-14-257.

7.

The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.

Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Singer CF, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C, Ferree S, Liu S, Cowens JW, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2014 Mar 1;20(5):1298-305. doi: 10.1158/1078-0432.CCR-13-1845. Epub 2014 Feb 11.

8.

Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma.

Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H, Altevogt P.

Oncotarget. 2014 Jan 30;5(2):462-72.

9.

A standardized staining protocol for L1CAM on formalin-fixed, paraffin-embedded tissues using automated platforms.

Fogel M, Harari A, Müller-Holzner E, Zeimet AG, Moldenhauer G, Altevogt P.

Int J Biol Markers. 2014 Jun 25;29(2):e180-3. doi: 10.5301/jbm.5000055.

PMID:
24242293
10.

Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response.

Hannesdóttir L, Tymoszuk P, Parajuli N, Wasmer MH, Philipp S, Daschil N, Datta S, Koller JB, Tripp CH, Stoitzner P, Müller-Holzner E, Wiegers GJ, Sexl V, Villunger A, Doppler W.

Eur J Immunol. 2013 Oct;43(10):2718-29. doi: 10.1002/eji.201242505. Epub 2013 Jul 11.

11.

L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.

Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M.

J Natl Cancer Inst. 2013 Aug 7;105(15):1142-50. doi: 10.1093/jnci/djt144. Epub 2013 Jun 18. Erratum in: J Natl Cancer Inst. 2013 Nov 20;105(22):1763.

PMID:
23781004
12.

Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens.

Schirmer U, Fiegl H, Pfeifer M, Zeimet AG, Müller-Holzner E, Bode PK, Tischler V, Altevogt P.

BMC Cancer. 2013 Mar 26;13:156. doi: 10.1186/1471-2407-13-156. Erratum in: BMC Cancer. 2018 Oct 29;18(1):1047.

13.

Polymorphisms in the gene regions of the adaptor complex LAMTOR2/LAMTOR3 and their association with breast cancer risk.

De Araujo ME, Erhart G, Buck K, Müller-Holzner E, Hubalek M, Fiegl H, Campa D, Canzian F, Eilber U, Chang-Claude J, Coassin S, Haun M, Kedenko L, Paulweber B, Reitsamer R, Himmel I, Flesch-Janys D, Lamina C, Kronenberg F, Huber LA, Kloss-Brandstätter A.

PLoS One. 2013;8(1):e53768. doi: 10.1371/journal.pone.0053768. Epub 2013 Jan 16.

14.

Ovarian cancer stem cells.

Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, Wiedemair AM, Rumpold H, Untergasser G, Concin N, Hofstetter G, Muller-Holzner E, Fiegl H, Marth C, Wolf D, Pesta M, Hatina J.

Neoplasma. 2012;59(6):747-55. doi: 10.4149/neo_2012_094. Review.

PMID:
22862176
15.

MMTV-neu mice deficient in STAT1 are susceptible to develop ovarian teratomas.

Hannesdóttir L, Daschil N, Philipp S, Tymoszuk P, Müller-Holzner E, Klima G, Verdorfer I, Doppler W.

Int J Dev Biol. 2012;56(4):279-83. doi: 10.1387/ijdb.113397lh.

16.

Detection of human papillomavirus type 18 E7 oncoprotein in cervical smears: a feasibility study.

Ehehalt D, Lener B, Pircher H, Dreier K, Pfister H, Kaufmann AM, Frangini S, Ressler S, Müller-Holzner E, Schmitt M, Höfler D, Rostek U, Kaiser A, Widschwendter A, Zwerschke W, Jansen-Dürr P.

J Clin Microbiol. 2012 Feb;50(2):246-57. doi: 10.1128/JCM.01108-11. Epub 2011 Nov 30.

17.

MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.

Hofstetter G, Berger A, Bauer EM, Schuster E, Wolf A, Chamson M, Müller-Holzner E, Reimer D, Braicu EI, Sehouli J, Ulmer H, Cacsire Castillo-Tong D, Zeillinger R, Concin N.

Oncol Rep. 2012 Mar;27(3):673-7. doi: 10.3892/or.2011.1560. Epub 2011 Nov 23.

PMID:
22134502
18.

Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients.

Goebel G, Berger R, Strasak AM, Egle D, Müller-Holzner E, Schmidt S, Rainer J, Presul E, Parson W, Lang S, Jones A, Widschwendter M, Fiegl H.

Br J Cancer. 2012 Jan 3;106(1):189-98. doi: 10.1038/bjc.2011.510. Epub 2011 Nov 22.

19.

Clinical relevance of TAp73 and ΔNp73 protein expression in ovarian cancer: a series of 83 cases and review of the literature.

Hofstetter G, Berger A, Chamson M, Müller-Holzner E, Reimer D, Ulmer H, Uramoto H, Marth C, Zeimet AG, Zeillinger R, Concin N.

Int J Gynecol Pathol. 2011 Nov;30(6):527-31. doi: 10.1097/PGP.0b013e31821ac519. Review. Erratum in: Int J Gynecol Pathol. 2012 May;31(3):296. G Zeimet, A [corrected to Zeimet, Alain G]. Int J Gynecol Pathol. 2012 Mar;31(2):191. Zeimet, Alain G [corrected to G Zeimet, A].

PMID:
21979586
20.

Fatal invasive cervical cancer secondary to untreated cervical dysplasia: a case report.

Braun S, Reimer D, Strobl I, Wieland U, Wiesbauer P, Müller-Holzner E, Fessler S, Scherer A, Marth C, Zeimet AG.

J Med Case Rep. 2011 Jul 18;5:316. doi: 10.1186/1752-1947-5-316.

21.

Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer.

Reimer D, Hubalek M, Kiefel H, Riedle S, Skvortsov S, Erdel M, Hofstetter G, Concin N, Fiegl H, Müller-Holzner E, Marth C, Altevogt P, Zeimet AG.

Oncogene. 2011 Sep 22;30(38):4038-49. doi: 10.1038/onc.2011.119. Epub 2011 Apr 25.

PMID:
21516127
22.

Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients.

Göbel G, Auer D, Gaugg I, Schneitter A, Lesche R, Müller-Holzner E, Marth C, Daxenbichler G.

Breast Cancer Res Treat. 2011 Nov;130(1):109-17. doi: 10.1007/s10549-010-1335-8. Epub 2011 Jan 8.

PMID:
21221769
23.

Subcellular localization of the human papillomavirus 16 E7 oncoprotein in CaSki cells and its detection in cervical adenocarcinoma and adenocarcinoma in situ.

Dreier K, Scheiden R, Lener B, Ehehalt D, Pircher H, Müller-Holzner E, Rostek U, Kaiser A, Fiedler M, Ressler S, Lechner S, Widschwendter A, Even J, Capesius C, Jansen-Dürr P, Zwerschke W.

Virology. 2011 Jan 5;409(1):54-68. doi: 10.1016/j.virol.2010.09.024. Epub 2010 Oct 23.

24.

E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer.

Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Concin N, Fiegl H, Müller-Holzner E, Marth C, Illmensee K, Altevogt P, Zeimet AG.

Cancer Res. 2010 Jun 1;70(11):4613-23. doi: 10.1158/0008-5472.CAN-09-3551. Epub 2010 May 11.

25.

Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature.

Klotz RK, Müller-Holzner E, Fessler S, Reimer DU, Zervomanolakis I, Seeber B, Mattle V, Wildt L.

Exp Clin Endocrinol Diabetes. 2010 May;118(5):291-7. doi: 10.1055/s-0029-1225351. Epub 2010 Mar 2.

PMID:
20198556
26.

Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors.

Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, Hauser-Kronberger C, Reitsamer R, Egle D, Reimer D, Müller-Holzner E, Jones A, Widschwendter M.

Cancer Sci. 2010 Apr;101(4):1059-66. doi: 10.1111/j.1349-7006.2010.01491.x. Epub 2010 Jan 12.

27.

Breast cancer in women: evaluation of benign and malignant axillary lymph nodes with contrast-enhanced ultrasound.

Steppan I, Reimer D, Müller-Holzner E, Marth C, Aigner F, Frauscher F, Frede T, Zeimet AG.

Ultraschall Med. 2010 Feb;31(1):63-7. doi: 10.1055/s-0028-1109847. Epub 2010 Jan 21. English, German.

PMID:
20094979
28.

Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas.

Huszar M, Pfeifer M, Schirmer U, Kiefel H, Konecny GE, Ben-Arie A, Edler L, Münch M, Müller-Holzner E, Jerabek-Klestil S, Abdel-Azim S, Marth C, Zeimet AG, Altevogt P, Fogel M.

J Pathol. 2010 Apr;220(5):551-61. doi: 10.1002/path.2673.

PMID:
20077528
29.

Infiltrating CD11b+CD11c+ cells have the potential to mediate inducible nitric oxide synthase-dependent cell death in mammary carcinomas of HER-2/neu transgenic mice.

Parajuli N, Müller-Holzner E, Böck G, Werner ER, Villunger A, Doppler W.

Int J Cancer. 2010 Feb 15;126(4):896-908. doi: 10.1002/ijc.24805.

30.

Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer.

Zeimet AG, Reimer D, Wolf D, Fiegl H, Concin N, Wiedemair A, Wolf AM, Rumpold H, Müller-Holzner E, Marth C.

Int J Cancer. 2009 May 15;124(10):2353-60. doi: 10.1002/ijc.24214.

31.

Activated p38-MAPK and gemcitabine sensitivity in recurrent ovarian cancer.

Klotz R, Zeimet AG, Reimer D, Müller-Holzner E, Chamson M, Marth C.

Anticancer Res. 2008 Sep-Oct;28(5B):2975-80.

32.

Practice of HER-2 immunohistochemistry in breast carcinoma in Austria.

Reiner-Concin A, Regitnig P, Dinges HP, Höfler G, Lax S, Müller-Holzner E, Obrist P, Rudas M.

Pathol Oncol Res. 2008 Sep;14(3):253-9. doi: 10.1007/s12253-008-9079-z. Epub 2008 Aug 28.

PMID:
18752057
33.

Validation of intraoperative risk assessment on frozen section for surgical management of endometrial carcinoma.

Egle D, Grissemann B, Zeimet AG, Müller-Holzner E, Marth C.

Gynecol Oncol. 2008 Sep;110(3):286-92. doi: 10.1016/j.ygyno.2008.05.007. Epub 2008 Jul 23.

PMID:
18653219
34.

Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer.

Auer D, Reimer D, Porto V, Fleischer M, Roessler J, Wiedemair A, Marth C, Müller-Holzner E, Daxenbichler G, Zeimet AG.

Breast Cancer Res Treat. 2009 Jul;116(1):103-11. doi: 10.1007/s10549-008-0108-0. Epub 2008 Jul 10.

PMID:
18618240
35.

Fallopian tube cancer associated with paraneoplastic dermatomyositis -- asymptomatic multivisceral exacerbated dermatomyositis mimicking recurrent widespread malignant disease: case report.

Seeber J, Reimer D, Müller-Holzner E, Spizzo G, Sepp N, Wiesbauer P, Marth C, Zeimet AG.

Eur J Gynaecol Oncol. 2008;29(2):168-70.

PMID:
18459555
36.

High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma.

Ressler S, Scheiden R, Dreier K, Laich A, Müller-Holzner E, Pircher H, Morandell D, Stein I, Viertler HP, Santer FR, Widschwendter A, Even J, Jansen-Dürr P, Capesius C, Zwerschke W.

Clin Cancer Res. 2007 Dec 1;13(23):7067-72.

37.

Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions.

Salani R, Davidson B, Fiegl M, Marth C, Müller-Holzner E, Gastl G, Huang HY, Hsiao JC, Lin HS, Wang TL, Lin BL, Shih IeM.

Clin Cancer Res. 2007 Oct 1;13(19):5805-9.

38.

Favorable prognostic value of SOCS2 and IGF-I in breast cancer.

Haffner MC, Petridou B, Peyrat JP, Révillion F, Müller-Holzner E, Daxenbichler G, Marth C, Doppler W.

BMC Cancer. 2007 Jul 25;7:136.

39.

Ovarian cancer specific kallikrein profile in effusions.

Shih IeM, Salani R, Fiegl M, Wang TL, Soosaipillai A, Marth C, Müller-Holzner E, Gastl G, Zhang Z, Diamandis EP.

Gynecol Oncol. 2007 May;105(2):501-7. Epub 2007 Feb 15.

PMID:
17303231
40.

Soluble isoforms but not the transmembrane form of coxsackie-adenovirus receptor are of clinical relevance in epithelial ovarian cancer.

Reimer D, Steppan I, Wiedemair A, Concin N, Hofstetter G, Marth C, Müller-Holzner E, Zeimet AG.

Int J Cancer. 2007 Jun 15;120(12):2568-75.

41.

Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients.

Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, Müller-Holzner E, Marth C, Zeimet AG.

Clin Cancer Res. 2007 Jan 1;13(1):144-51.

42.

Sentinel node detection with the blue dye technique in early cervical cancer.

Schwendinger V, Müller-Holzner E, Zeimet AG, Marth C.

Eur J Gynaecol Oncol. 2006;27(4):359-62.

PMID:
17009626
43.

Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer.

Fiegl H, Millinger S, Goebel G, Müller-Holzner E, Marth C, Laird PW, Widschwendter M.

Cancer Res. 2006 Jan 1;66(1):29-33.

44.

The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C.

Clin Cancer Res. 2005 Dec 1;11(23):8326-31.

45.

Expression of the high-risk human papillomavirus type 18 and 45 E7 oncoproteins in cervical carcinoma biopsies.

Fiedler M, Ressler S, Campo-Fernández B, Laich A, Jansen L, Widschwendter A, Viertler HP, Bacher N, Morandell D, Müller-Holzner E, Dürst M, Jansen-Dürr P, Zwerschke W.

J Gen Virol. 2005 Dec;86(Pt 12):3235-41.

PMID:
16298968
46.

Interferon-gamma expression is an independent prognostic factor in ovarian cancer.

Marth C, Fiegl H, Zeimet AG, Müller-Holzner E, Deibl M, Doppler W, Daxenbichler G.

Am J Obstet Gynecol. 2004 Nov;191(5):1598-605.

PMID:
15547530
47.

DNA hypomethylation is prevalent even in low-grade breast cancers.

Jackson K, Yu MC, Arakawa K, Fiala E, Youn B, Fiegl H, Müller-Holzner E, Widschwendter M, Ehrlich M.

Cancer Biol Ther. 2004 Dec;3(12):1225-31. Epub 2004 Dec 9. Review.

PMID:
15539937
48.

Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool.

Müller HM, Millinger S, Fiegl H, Goebel G, Ivarsson L, Widschwendter A, Müller-Holzner E, Marth C, Widschwendter M.

Clin Chem. 2004 Nov;50(11):2171-3. No abstract available.

49.

DNA hypomethylation and ovarian cancer biology.

Widschwendter M, Jiang G, Woods C, Müller HM, Fiegl H, Goebel G, Marth C, Müller-Holzner E, Zeimet AG, Laird PW, Ehrlich M.

Cancer Res. 2004 Jul 1;64(13):4472-80.

50.

Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen.

Widschwendter M, Siegmund KD, Müller HM, Fiegl H, Marth C, Müller-Holzner E, Jones PA, Laird PW.

Cancer Res. 2004 Jun 1;64(11):3807-13.

Supplemental Content

Loading ...
Support Center